LAMZEDE Trademark

Trademark Overview

On Tuesday, March 29, 2016, a trademark application was filed for LAMZEDE with the United States Patent and Trademark Office. The USPTO has given the LAMZEDE trademark a serial number of 79189146. The federal status of this trademark filing is SECTION 71 ACCEPTED as of Wednesday, December 6, 2023. This trademark is owned by CHIESI FARMACEUTICI S.P.A.. The LAMZEDE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of [ respiratory diseases, cardiovascular disorders, gastrointestinal, ] musculoskeletal, neurological diseases and disorders; anti-inflammatory and anti-rheumatics drugs
lamzede

General Information

Serial Number79189146
Word MarkLAMZEDE
Filing DateTuesday, March 29, 2016
Status706 - SECTION 71 ACCEPTED
Status DateWednesday, December 6, 2023
Registration Number5075931
Registration DateTuesday, November 8, 2016
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 23, 2016

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of [ respiratory diseases, cardiovascular disorders, gastrointestinal, ] musculoskeletal, neurological diseases and disorders; anti-inflammatory and anti-rheumatics drugs

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, July 18, 2016
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCHIESI FARMACEUTICI S.P.A.
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressPARMA (PR) I-43122
IT
Party NameCHIESI FARMACEUTICI S.P.A.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressIT
Party NameCHIESI FARMACEUTICI S.P.A.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressIT

Trademark Events

Event DateEvent Description
Thursday, July 14, 2016SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, July 15, 2016LIMITATION FROM ORIGINAL APPLICATION ENTERED
Monday, July 18, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, July 18, 2016ASSIGNED TO EXAMINER
Monday, July 18, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, July 22, 2016APPLICATION FILING RECEIPT MAILED
Wednesday, August 3, 2016NOTICE OF PUBLICATION
Wednesday, August 10, 2016NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, August 10, 2016NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Tuesday, August 23, 2016PUBLISHED FOR OPPOSITION
Friday, October 21, 2016NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Tuesday, November 8, 2016REGISTERED-PRINCIPAL REGISTER
Thursday, December 8, 2016GRANT OF PROTECTION CREATED, TO BE SENT TO IB
Thursday, December 8, 2016FINAL DISPOSITION PROCESSED
Thursday, December 8, 2016FINAL DISPOSITION NOTICE SENT TO IB
Friday, December 23, 2016NOTIFICATION PROCESSED BY IB
Saturday, November 20, 2021NEW REPRESENTATIVE AT IB RECEIVED
Thursday, April 20, 2023TEAS SECTION 71 RECEIVED
Tuesday, December 5, 2023CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Wednesday, December 6, 2023REGISTERED-SEC.71 ACCEPTED
Wednesday, December 6, 2023NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Wednesday, August 7, 2024PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Tuesday, August 13, 2024GENERIC MADRID TRANSACTION CREATED
Wednesday, August 14, 2024GENERIC MADRID TRANSACTION SENT TO IB
Saturday, November 9, 2024PARTIAL INVALIDATION PROCESSED BY THE IB
Thursday, August 14, 2025NEW REPRESENTATIVE AT IB RECEIVED
Saturday, November 8, 2025COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED

Related Keywords

lamzede anti diseases disorders preparations inflammatory rheumatics drugs neurological musculoskeletal treatment